ADAR1 Capital Management, LLC 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 8:27 pm Purchase | 2025-06-30 | 13G | Inhibikase Therapeutics, Inc. IKT | ADAR1 Capital Management, LLC | 7,737,694 9.900% | 743,448 (+10.63%) | Filing |
| 2025-02-14 9:04 pm Purchase | 2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT | ADAR1 Capital Management, LLC | 6,994,246 9.990% | 6,994,246 (New Position) | Filing |